Skip to main content
SpringerLink
Log in

Treat hyperhidrosis with topical therapies first, then dermatological or systemic therapies

  • Practical Issues and Updates
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Hyperhidrosis (HH) includes chronic focal primary HH (PHH) stemming from sweat gland overactivity, and generalised secondary HH (SHH), which warrants investigation for an underlying cause. PHH, which may be axillary, plantar, palmar and/or craniofacial, decreases patients’ quality of life and often goes undiagnosed. Topical therapies, starting with aluminium chloride, are often effective. Additional recommendations for severe or recalcitrant PHH, and in craniofacial HH, are iontophoresis, topical or systemic anticholinergic agents and onabotulinum toxin injections.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Henning MAS, Bouazzi D, Jemec GBE. Treatment of hyperhidrosis: an update. Am J Clin Dermatol. 2022;23(5):635–46.

    Article  PubMed  Google Scholar 

  2. McConaghy JR, Fosselman D. Hyperhidrosis: management options. Am Fam Physician. 2018;97(11):729–34.

    PubMed  Google Scholar 

  3. Kisielnicka A, Szczerkowska-Dobosz A, Purzycka-Bohdan D, et al. Hyperhidrosis: disease aetiology, classification and management in the light of modern treatment modalities. Postepy Dermatol Alergol. 2022;39(2):251–7.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Solish N, Bertucci V, Dansereau A, et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg. 2007;33(8):908–23.

    CAS  PubMed  Google Scholar 

  5. International Hyperhidrosis Society. Primary focal palmar. 2012. https://www.sweathelp.org. Accessed 20 Apr 2023.

  6. Wilke K, Martin A, Terstegen L, et al. Neurobiology of skin appendages: eccrine, apocrine, and apoeccrine sweat glands. In: Granstein RD, Luger TA, editors., et al., Neuroimmunology of the skin. Berlin: Springer; 2009.

    Google Scholar 

  7. Hornberger J, Grimes K, Naumann M, et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol. 2004;51(2):274–86.

    Article  PubMed  Google Scholar 

  8. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–6.

    Article  CAS  PubMed  Google Scholar 

  9. Thianboonsong T, Kanokrungsee S, Paichitrojjana A, et al. Efficacy and tolerability of 20% aluminum sesquichlorohydrate vs 20% aluminum chloride for the treatment of axillary hyperhidrosis: a randomized controlled trial. Dermatol Ther. 2020;33(6):e14354.

    Article  CAS  PubMed  Google Scholar 

  10. Streker M, Reuther T, Hagen L, et al. Hyperhidrosis plantaris—a randomized, half-side trial for efficacy and safety of an antiperspirant containing different concentrations of aluminium chloride. J Dtsch Dermatol Ges. 2012;10(2):115–9.

    PubMed  Google Scholar 

  11. Masur C, Soeberdt M, Kilic A, et al. Safety and efficacy of topical formulations containing 0·5, 1 and 2% glycopyrronium bromide in patients with primary axillary hyperhidrosis: a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2020;182(1):229–31.

    CAS  PubMed  Google Scholar 

  12. Abels C, Soeberdt M, Kilic A, et al. A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial. Br J Dermatol. 2021;185(2):315–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Yokozeki H, Fujimoto T, Wanatabe S, et al. Topical glycopyrronium tosylate in Japanese patients with primary axillary hyperhidrosis: a randomized, double-blind, vehicle-controlled study. J Dermatol. 2022;49(1):86–94.

    Article  CAS  PubMed  Google Scholar 

  14. Glaser DA, Hebert AA, Nast A, et al. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2019;80(1):128-38.e2.

    Article  CAS  PubMed  Google Scholar 

  15. Pariser DM, Hebert AA, Drew J, et al. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: patient-reported outcomes from the ATMOS-1 and ATMOS-2 phase III randomized controlled trials. Am J Clin Dermatol. 2019;20(1):135–45.

    Article  PubMed  Google Scholar 

  16. Kirsch B, Smith S, Cohen J, et al. Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: a phase II, randomized, controlled, double-blinded trial. J Am Acad Dermatol. 2020;82(6):1321–7.

    Article  CAS  PubMed  Google Scholar 

  17. Yokozeki H, Fujimoto T, Abe Y, et al. A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis. J Dermatol. 2021;48(3):279–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Artzi O, Loizides C, Zur E, et al. Topical oxybutynin 10% gel for the treatment of primary focal hyperhidrosis: a randomized double-blind placebo-controlled split area study. Acta Derm Venereol. 2017;97(9):1120–4.

    Article  CAS  PubMed  Google Scholar 

  19. Lueangarun S, Sermsilp C, Tempark T. Topical botulinum toxin type A liposomal cream for primary axillary hyperhidrosis: a double-blind, randomized, split-site, vehicle-controlled study. Dermatol Surg. 2018;44(6):e14354.

    Google Scholar 

  20. Wade R, Llewellyn A, Jones-Diette J, et al. Interventional management of hyperhidrosis in secondary care: a systematic review. Br J Dermatol. 2018;179(3):599–608.

    Article  CAS  PubMed  Google Scholar 

  21. Obed D, Salim M, Bingoel AS, et al. Botulinum toxin versus placebo: a meta-analysis of treatment and quality-of-life outcomes for hyperhidrosis. Aesthetic Plast Surg. 2021;45(4):1783–91.

    Article  PubMed  PubMed Central  Google Scholar 

  22. International Hyperhidrosis Society. Systemic medication. 2018. https://www.sweathelp.org. Accessed 20 Apr 2023.

  23. Dr Reddy’s Laboratories Ltd. Glycopyrrolate tablets: US prescribing information. 2016. https://dailymed.nlm.nih.gov. Accessed 20 Apr 2023.

  24. Rising Pharmaceuticals Inc. Oxybutynin chloride tablets: US prescribing information. 2018. https://dailymed.nlm.nih.gov. Accessed 20 Apr 2023.

  25. National Institute for Health and Care Excellence. Hyperhidrosis: oral glycopyrronium bromide. 2013. www.nice.org.uk/guidance/esuom16. Accessed 20 Apr 2023.

  26. Wolosker N, Campos JRM, Kauffman P, et al. A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis. J Vasc Surg. 2012;55(6):1696–700.

    Article  PubMed  Google Scholar 

  27. Schollhammer M, Brenaut E, Menard-Andivot N, et al. Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial. Br J Dermatol. 2015;173(5):1163–8.

    Article  CAS  PubMed  Google Scholar 

  28. ESTEVE. Vagantin® RIEMSER 50 mg coated tablets: German prescribing information. 2020. https://www.esteve.com/de/produkte/vagantin. Accessed 20 Apr 2023.

  29. Müller C, Berensmeier A, Hamm H, et al. Efficacy and safety of methantheline bromide (Vagantin(®) ) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo-controlled trial. J Eur Acad Dermatol Venereol. 2013;27(10):1278–84.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Caroline Fenton & Connie Kang

Authors
  1. Caroline Fenton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Connie Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Connie Kang.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and conflict of interest

C. Fenton, a contracted employee of Adis International Ltd/Springer Nature, and C. Kang, a salaried employee of Adis International Ltd/Springer Nature, declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability

Not applicable.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fenton, C., Kang, C. Treat hyperhidrosis with topical therapies first, then dermatological or systemic therapies. Drugs Ther Perspect 39, 200–206 (2023). https://doi.org/10.1007/s40267-023-00996-0

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-023-00996-0

Search

Navigation